A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

Exclusion criteria

• ✕. Chronic administration of oral and/or parenteral steroids at doses considered sufficiently immunosuppressive (example, greater than and equal to \[\>=\] 2 milligrams per kilograms \[mg/kg\] body weight/day prednisone \[or equivalent\] for \>=14 consecutive days or \>=20 mg/day prednisone \[or equivalent\] administered for \>=14 consecutive days) within 60 days prior to Day 1 (Month \[M\] 0) (note: use of corticosteroids by inhaled, intranasal, intra-articular, bursal, tendon injection, or topical routes is allowed).
• ✕. Receipt of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.
• ✕. Receipt of immunostimulants within 60 days prior to Day 1 (M0).
• ✕. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).
• ✕. Human immunodeficiency virus (HIV) infection or HIV-related disease.
• ✕. Hepatitis B virus infection.
• ✕. Hepatitis C virus infection.
• ✕. Genetic immunodeficiency. 7. Participant has known or suspected abnormalities of splenic or thymic function.